2022 CPIC指南:CYP2C19基因型与氯吡格雷治疗(更新版)

2022-01-16 临床药物基因组学实施联盟 Clin Pharmacol Ther

2022年1月,临床药物基因组学实施联盟(CPIC)更新发布了CYP2C19基因型与氯吡格雷治疗指南。CYP2C19催化抗血小板前药氯吡格雷的生物活性,CYP2C19基因型影响氯吡格雷活性代谢物的形成

中文标题:

2022 CPIC指南:CYP2C19基因型与氯吡格雷治疗(更新版)

英文标题:

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

发布日期:

2022-01-16

简要介绍:

2022年1月,临床药物基因组学实施联盟(CPIC)更新发布了CYP2C19基因型与氯吡格雷治疗指南。CYP2C19催化抗血小板前药氯吡格雷的生物活性,CYP2C19基因型影响氯吡格雷活性代谢物的形成。接受氯吡格雷治疗的CYP2C19中间代谢和代谢不良者的血小板控制率降低,主要不良心脑血管事件风险增加。本文是对2013年版CYP2C19基因型与氯吡格雷治疗指南的更新。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2022 CPIC指南:CYP2C19基因型与氯吡格雷治疗(更新版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=f9fa61c002a364c8, title=2022 CPIC指南:CYP2C19基因型与氯吡格雷治疗(更新版), enTitle=Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update, guiderFrom=Clin Pharmacol Ther, authorId=0, author=, summary=2022年1月,临床药物基因组学实施联盟(CPIC)更新发布了CYP2C19基因型与氯吡格雷治疗指南。CYP2C19催化抗血小板前药氯吡格雷的生物活性,CYP2C19基因型影响氯吡格雷活性代谢物的形成, cover=https://img.medsci.cn/20220513/1652448863699_1608702.jpg, journalId=0, articlesId=null, associationId=1236, associationName=临床药物基因组学实施联盟, associationIntro=, copyright=0, guiderPublishedTime=Sun Jan 16 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">2022年1月,临床药物基因组学实施联盟(CPIC)更新发布了CYP2C19基因型与氯吡格雷治疗指南。CYP2C19催化抗血小板前药氯吡格雷的生物活性,CYP2C19基因型影响氯吡格雷活性代谢物的形成。接受氯吡格雷治疗的CYP2C19中间代谢和代谢不良者的血小板控制率降低,主要不良心脑血管事件风险增加。本文是对2013年版CYP2C19基因型与氯吡格雷治疗指南的更新。</span></p>, tagList=[TagDto(tagId=504, tagName=氯吡格雷), TagDto(tagId=62517, tagName=CYP2C19基因型)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=19482, appHits=71, showAppHits=0, pcHits=652, showPcHits=19410, likes=0, shares=11, comments=4, approvalStatus=1, publishedTime=Sat May 14 15:31:00 CST 2022, publishedTimeString=2022-01-16, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Fri May 13 21:38:04 CST 2022, updatedBy=6477789, updatedName=MS南菜园, updatedTime=Sat Jan 06 21:38:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 CPIC指南:CYP2C19基因型与氯吡格雷治疗(更新版).pdf)])
2022 CPIC指南:CYP2C19基因型与氯吡格雷治疗(更新版).pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1220268, encodeId=e0351220268cd, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Tue May 17 12:09:41 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219627, encodeId=69cb121962ea4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Sat May 14 19:03:54 CST 2022, time=2022-05-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1220268, encodeId=e0351220268cd, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Tue May 17 12:09:41 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219627, encodeId=69cb121962ea4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37515579911, createdName=ms1000001982939558, createdTime=Sat May 14 19:03:54 CST 2022, time=2022-05-14, status=1, ipAttribution=)]
    2022-05-14 ms1000001982939558

    学习了

    0